SG Tylor
Delcath Triumphs After Years: FDA Grants Approval to Hepzato Kit for Treating Metastatic Uveal Melanoma
After enduring nearly a decade of setbacks, Delcath has finally achieved a regulatory milestone in the United States. Delaware-based Delcath ...
COVID-19 Vaccine Makers Prepare for Private-Market Launches Amid Evolving Variants
Following a decline in demand for COVID-19 vaccines, prominent biopharmaceutical companies are gearing up for private-market launches this upcoming fall. ...
Regeneron Faces New Challenges as Biosimilars Target Eylea Market Dominance, Novartis’ Sandoz Takes Aim with Therapeutic Equivalence
Regeneron finds itself at a crossroads as its blockbuster eye drug Eylea contends with an FDA rejection and growing competition ...
Novo Nordisk and Eli Lilly Ride Obesity and Diabetes Drugs to the Forefront in Q2 Pharmaceutical Performance
As the COVID-19 pandemic surged and waned, the biopharmaceutical industry witnessed a rollercoaster ride of revenue spikes and troughs. However, ...
Amgen Takes a Playful Approach with Otezla Advertisement Amid Growing Competition in the Psoriasis Market
Amgen, a major biotech company, has taken an innovative approach to connect with psoriasis patients by using humor in their ...
Japanese Government Backs Arcalis with $115 Million Grants for mRNA Vaccine Production
Following Daiichi Sankyo’s recent accomplishment of securing Japan’s first mRNA vaccine approval, a potential competitor has emerged backed by significant ...
GeneFab Secures $38 Million Deal to Utilize Senti Biosciences’ Advanced Manufacturing Facility
In a major development, GeneFab, a newly established organization specializing in contract research, development, and manufacturing for cell and gene ...
Revance into Therapeutic Realm with FDA Approval for Cervical Dystonia Treatment, Daxxify
Revance, a prominent player in the aesthetics market, has now made a strategic move into the promising therapeutic arena. Following ...
Pfizer’s Elrexfio Gets FDA Nod, Ignites Showdown with J&J in Multiple Myeloma Arena
Pfizer’s latest BCMA-targeted drug, Elrexfio (elranatamab), has gained FDA approval for treating multiple myeloma patients who have undergone at least ...
How Pfizer Defends Its Heart Drug Vyndamax from Generics
Just within four years of introducing their premium heart medication Vyndamax, Pfizer finds itself embroiled in a patent defense battle ...
Regulatory Authority Raises Concerns Over Novartis’ Entresto Podcast Marketing Assertions
Novartis, a trailblazer in digital pharma innovation for years, now faces the intricate labyrinth of regulatory compliance. This complex challenge ...
Thermo Fisher Cuts Over 200 Jobs at Clinical-Stage Cell and Gene Therapy Facility in Florida
In the midst of ongoing workforce reductions impacting the biotech sector, even prominent players like Bristol Myers Squibb, Emergent BioSolutions, ...
Johnson & Johnson Breaks Into Prostate Cancer Market with Akeega
After the FDA’s green light for AstraZeneca/Merck and Pfizer’s PARP inhibitors, Johnson & Johnson (J&J) has now secured its own ...
Novartis Acquires Chinook Therapeutics for USD 3.5 Billion to Boost its Renal Portfolio
Novartis, a global pharmaceutical giant, has finalized its deal to buy Chinook Therapeutics, a biotech company that specializes in developing ...
Gene Therapy Vector Lawsuit: Henrietta Lacks’ Estate Targets Ultragenyx Over Exploitation
Just under a month after reaching a settlement with Thermo Fisher over the utilization of Henrietta Lacks’ cells, her family ...
Legal Battle Unfolds as Endo’s Par Pharmaceuticals Defends Exclusive Rights to Chantix Amid Generic Rivalry
Following the recall of Pfizer’s smoking cessation drug Chantix in 2021, Endo’s subsidiary Par Pharmaceuticals has stood as the sole ...
Amylyx Pharmaceuticals Shines with ALS Drug’s Relyvrio’s Strong Performance and Promising Path Forward
Amylyx Pharmaceuticals continues to impress the financial world with its amyotrophic lateral sclerosis (ALS) drug, Relyvrio. The medication, known by ...
BMS Layoffs Over 100 Employees Lose Jobs After Earnings Miss
Bristol Myers Squibb, a prominent pharmaceutical company headquartered in New Jersey, has undertaken a significant reorganization of its financial structure ...
How Heartburn Medicine May Increase Your Risk of Dementia
A recent study suggests that long-term use of certain heartburn medicines (acid reflux drugs) may increase your risk of developing ...
Pembrolizumab Frontline Use With Lenvatinib Supported in nccRCC
Combining pembrolizumab (Keytruda) with lenvatinib (Lenvima) has showcased enduring effectiveness against tumors in patients with non-clear cell renal cell carcinoma ...
Juli App: A Revolutionary AI Solution for Asthma and Depression
Juli, an AI-driven platform designed to aid individuals in managing chronic health conditions, has demonstrated significant improvements in two separate ...
Drug shortages, according to US chemists, are impacting cancer treatment
A recent survey conducted by the American Society of Hospital Pharmacists (ASHP) has revealed that over 50% of hospital pharmacists ...
Wegovy from Novo Nordisk surges, reaching $1 billion in just one quarter
For Novo overall, there’s “a lot to be proud of” in 2023’s second quarter, the company’s head of North American ...
Genentech was fined $158K by the EPA for improper management of hazardous waste at a site in San Francisco
After reaching an agreement with the US Environmental Protection Agency (EPA) to address environmental violations at a former facility, Genentech ...
Regeneron’s High-Dose Eylea Demonstrates Persistence as FDA Decision Looms
While awaiting an FDA decision regarding a higher-dose version of Eylea (aflibercept), Regeneron has consistently emphasized the durability of their ...
Babylon shutters its US operations after a failed rescue merger deal
Babylon Health’s efforts to secure funding and stabilize its operations have been thwarted due to the collapse of a planned ...
Supreme Court Halts Purdue Pharma’s Bankruptcy Deal That Shielded Sacklers From Opioid Lawsuits
The Supreme Court has put a halt to a massive bankruptcy settlement that would have shielded Purdue Pharma and the ...
A2R, a prostate cancer medication, is discontinued by Arcus and Gilead
Arcus and Gilead Sciences have opted to discontinue the development of their A2 receptor antagonist, etrumadenant, for castration-resistant prostate cancer ...
eureKING purchases SCTbio to further its bio manufacturing initiative
eureKING, a special purpose acquisition company (SPAC) established last year with a substantial investment of over €150 million, has finalized ...
SK Bioscience invests $85M on a 7% share in the vaccine manufacturer, Novavax, to keep it afloat
Following its setback during the pandemic phase of COVID-19 with a delayed vaccine, Novavax is now aiming for recovery in ...
